ArticlePharmacology research & perspectives2025

The MAO-B Inhibitor Selegiline Reduces the Viability of Different Prostate Cancer Cell Lines and Enhances the Effects of Anti-Androgen and Cytostatic Agents.

Anita Steib et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.